Welcome to Adjuvant

We create value for companies advancing human healthcare.
We believe the advanced therapies and regenerative medicine technologies being developed today will transform medicine.
We are the Adjuvant to make this happen. Learn More

Who We Are

Why Adjuvant?

Who We Work With

* This is a partial list of our clients.

How We Do It

We have a process. It works, and is informed by experience.

  • Biotech Company Licensing Negotiation

    The Challenge

    THE CHALLENGE: : Regenerative medicine client needed to secure a portfolio of patents to establish freedom to operate in their field. The discussions had become competitive and the company had been told that another partner was selected for the license.

    Our Approach

    OUR APPROACH: : Adjuvant was brought in to reestablish discussions and build a case that the client company would be the best long-term commercial partner for the institution. By leveraging personal relationships, the client's scientific strengths, courting the support of the inventors, the client was reestablished as the partner of choice.

    Result

    THE RESULT: The client was able to license the portfolio of 14 patents giving them FTO in the field. Subsequently, some of the IP has proved to be seminal in the field and helped the client to raise investment and establish strategic partnerships.

  • Translational Funding Strategic Partnership

    The Challenge

    THE CHALLENGE: : The translational arm of a leading disease foundation sought to assess long-term opportunities to identify and fund promising research in its therapeutic focus area.

    Our Approach

    OUR APPROACH: : Adjuvant surveyed the market players and performed a gap analysis to identify areas where the foundation could create a long-term impact. Adjuvant played an active role in developing a program strategy and managing a key $30 million pharmaceutical company partnership.

    Result

    THE RESULT: The client launched its funding program resulting in $3 million in development grants to the first six companies.

  • Partnering of Regenerative Medicine Platform Technology

    The Challenge

    THE CHALLENGE: : A leading Regenerative Medicine company needed market analysis and target list of potential strategic partners for therapeutic application of the company’s platform technology.

    Our Approach

    OUR APPROACH: : Adjuvant conducted a broad partner analysis of over 400 potential world-wide companies. Adjuvant narrowed the prospective list to 72 and interviewed 38 companies based on specific criteria and complementary assets . Adjuvant then recommended 14 companies for further partnership discussion with the company.

    Result

    THE RESULT: The company is currently in discussions with 8 of the 14 companies recommended by Adjuvant for therapeutic application of the platform technology.

  • Regenerative Medicine Intellectual Property Landscape for Top 5 Pharma Company

    The Challenge

    THE CHALLENGE: : Top 5 pharma company completing due diligence on a new regenerative medicine business opportunity. The company did not have the domain expertise in house for an in depth Intellectual Property Commercial Assessment of the stem cell sector.

    Our Approach

    OUR APPROACH: : Adjuvant worked with the Vice President of Business Development and engaged in detailed research and domain specific analysis of the stem cell technology IP landscape.

    Result

    THE RESULT: Adjuvant delivered a comprehensive and in depth landscape of the stem cell technologies of interest, including technology description, worldwide intellectual property status, commercialization potential, and marketability of the competing intellectual property in the sector.

  • New Regenerative Medicine Center of Excellence at Top 5 Pharma Company

    The Challenge

    THE CHALLENGE: : A top 5 pharma company lacked in house expertise to develop a business model to support a regenerative medicine therapeutic area growth strategy.

    Our Approach

    OUR APPROACH: : Adjuvant applied deep regenerative medicine domain expertise and business strategy to assess trends impacting the cell therapy landscape, including aspects related to regulation, market access, intellectual property, and manufacturing. In addition, Adjuvant developed a comparative analysis of allogeneic and autologous business models, with emphasis on key differences from traditional pharma/biotech products.

    Result

    THE RESULT: Adjuvant delivered a comprehensive and detailed business plan for a Regenerative Medicine Center of Excellence. This product provided both business and scientific / clinical insight and rigorous analysis to deliver high impact insight and an actionable strategic plan for the company.

  • Venture Capital Due Diligence

    The Challenge

    THE CHALLENGE: : A leading venture capital firm needed to validate the market opportunity for a portfolio company developing an application for knowledge management and data integration in drug discovery. The client needed to assess the receptivity of large biotech and pharmaceutical companies to recognize the value of an integrated knowledge management application and identify a likely pricing model for the application.

    Our Approach

    OUR APPROACH: : Adjuvant identified and interviewed twenty decision-makers in drug discovery and bioinformatics in large biotech and pharmaceutical companies. We presented the product concept and tested the underlying market assumptions and several potential economic models for the product.

    Result

    THE RESULT: Adjuvant was able to validate the market need and propose a go-to-market strategy and pricing model. In addition, Adjuvant was able to identify six companies interested in discussing pilot evaluations of the client's product.

  • Commercial and Clinical Assessment of IP from a Leading Research Institute

    The Challenge

    THE CHALLENGE: A leading medical research institution needed objective assessments of their regenerative medicine IP portfolios to prioritize translational and tech transfer efforts.

    Our Approach

    OUR APPROACH Adjuvant reviewed entire portfolio and focused on a tissue engineering technology for commercialization. Adjuvant secured and managed a $350K internal university grant to accelerate the development of the technology prior to company formation. Clinical and market assessments were completed for both research tool and clinical application.

    Result

    THE RESULT Institution accepted and endorsed Adjuvant recommendation and is pursuing development of two of recommended programs.

  • Launch and Ongoing Management of the Alliance for Regenerative Medicine

    The Challenge

    THE CHALLENGE: Multiple clients in the regenerative medicine field highlighted the need for a consolidated and focused initiative to accelerate commercialization, increase investment in sector, and influence legislative, regulatory and reimbursement policy.

    Our Approach

    OUR APPROACH: Adjuvant developed a strategy to launch a 501c(4) non-profit called the Alliance for Regenerative Medicine to provide a voice and effect policy in regenerative medicine. Adjuvant orchestrated the launch, program development and membership recruitment.

    Result

    THE RESULT: Within four years, the organization has over 150 members and is executing a funded legislative, regulatory, investment and science & technology agenda defined by the member companies.

  • Specialty Pharmaceutical Marketed Product Acquisition

    The Challenge

    THE CHALLENGE: A regional subsidiary of a global specialty pharmaceutical company sought to acquire complementary products in their key therapeutic areas to add $10-15 million of near-term revenue while priming the marketplace for the launch of future products.

    Our Approach

    OUR APPROACH: Adjuvant conducted a comprehensive survey of ex-U.S. marketed products to identify un-promoted products available in the target geography.

    Result

    THE RESULT: Within two months, Adjuvant identified and qualified product acquisition candidates. Within five months, the company in-licensed a marketed product contributing $10 million+ in annual accretive revenue.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

How To Reach Us

WASHINGTON DC OFFICE:

Morrie Ruffin
Managing Partner
mruffin@adjuvant.com
202-345-3675

MINNEAPOLIS OFFICE:

Sarah Haecker Ph.D.
Chief Scientific Officer
shaecker@adjuvant.com
612-202-6805

SAN DIEGO OFFICE:

Bethany Kraynack
Vice President, Operations
bkraynack@adjuvant.com
858-229-9849

MAILING ADDRESS:

722 Dulaney Valley Road
Suite 262
Towson, MD 21204